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ligands such as naturally occurring DNA bases attached to a 
peptide backbone through a suitable linker. 
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MODULATION OF CELLULAR 
TRANSCRIPTION FACTOR ACTIVITY 
RELATED APPLICATION 
This patent application is related to US. Pat. No. 5,641, 
625. This patent application also is a divisional of Ser. No. 
08/088,661 now US. Pat. No. 6,228,982, ?led Jul. 2, 1993, 
Which is a continuation-in-part of Ser. No. 08/054,363 now 
US. Pat. No. 5,539,082, ?led Apr. 26, 1993, Which is a 
continuation-in-part of application PCT EP92/01219, ?led 
May 19, 1992 and published Nov. 26, 1992 as WO 
92/20702. The entire contents of each of the foregoing 
patent applications are incorporated herein by reference. 
FIELD OF THE INVENTION 
This invention is directed to generally linear compounds 
or “strands” Wherein naturally-occurring nucleobases or 
other nucleobase-binding moieties preferably are covalently 
bound to a polyamide backbone. In particular, the invention 
concerns compounds Wherein tWo such strands coordinate 
through hydrogen bonds to form a DNA-like double strand. 
BACKGROUND OF THE INVENTION 
The transcription and processing of genomic duplex DNA 
is controlled by generally proteinaceous transcription factors 
that recogniZe and bind to speci?c DNA sequences. One 
strategy for the control of gene expression is to add to a cell 
double-stranded DNA or double-stranded DNA-like struc 
tures that Will bind to the desired factor in preference to or 
in competition With genomic DNA, thereby inhibiting pro 
cessing of the DNA into a protein. This modulates the 
protein’s action Within the cell and can lead to bene?cial 
effects on cellular function. Naturally occurring or unmodi 
?ed oligonucleotides are unpractical for such use because 
they have short in vivo half-lives and they are poor cell 
membrane penetrators. 
These problems have resulted in an extensive search for 
improvements and alternatives. In order to improve half-life 
as Well as membrane penetration, a large number of varia 
tions in polynucleotide backbones has been undertaken. 
These variations include the use of methylphosphonates, 
phosphoro-thioates, phosphordithioates, phosphoramidates, 
phosphate esters, bridged phosphoroamidates, bridged 
phosphorothioates, bridged methylenephosphonates, 
dephospho internucleotide analogs With siloxane bridges, 
carbonate bridges, carboxymethyl ester bridges, acetamide 
bridges, carbamate bridges, thioether, sulfoxy, sulfono 
bridges, various “plastic” DNAs, ot-anomeric bridges, and 
borane derivatives. The great majority of these backbone 
modi?cations lead to decreased stability for hybrids formed 
betWeen the modi?ed oligonucleotide and its complemen 
tary native oligonucleotide, as assayed by measuring Tm 
values. 
Consequently, there remains a need in the art for stable 
compounds that can form double-stranded, helical structures 
mimicking double-stranded DNA. 
OBJECTS OF THE INVENTION 
It is one object of the present invention to provide 
compounds that mimic the double-helical structure of DNA. 
It is a further object of the invention to provide com 
pounds Wherein linear, polymeric strands coordinate 
through hydrogen bonds to form double helices. 
It is another object to provide compounds Wherein 
naturally-occurring nucleobases or other nucleobase 
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2 
binding moieties are covalently bound to a non-sugar 
phosphate backbone. 
It is yet another object to provide therapeutic, diagnostic, 
and prophylactic methods that employ such compounds. 
SUMMARY OF THE INVENTION 
The present invention provides a novel class of 
compounds, knoWn as peptide nucleic acids (PNAs), that 
can coordinate With one another or With single-stranded 
DNA to form double-stranded (i.e., duplex) structures. The 
compounds include homopolymeric PNA strands and het 
eropolymeric PNA strands (e.g., DNA/PNA strands), Which 
coordinate through hydrogen bonding to form helical struc 
tures. Duplex structures can be formed, for example, 
betWeen tWo complementary PNA or PNA/DNA strands or 
betWeen tWo complementary regions Within a single such 
strand. 
In certain embodiments, each strand of the double 
stranded compounds of the invention includes a sequence of 
ligands covalently bound by linking moieties and at least 
one of said linking moieties comprising an amide, 
thioamide, sul?namide or sulfonamide linkage. The ligands 
on one strand hydrogen bond With ligands on the other 
strand and, together, assume a double helical structure. The 
compounds of the invention preferably comprise ligands 
linked to a polyamide backbone. Representative ligands 
include either the four main naturally occurring DNA bases 
(i.e., thymine, cytosine, adenine or guanine) or other natu 
rally occurring nucleobases (e.g., inosine, uracil, 
5-methylcytosine or thiouracil) or arti?cial bases (e.g., 
bromothymine, aZaadenines or aZaguanines, 
5-propynylthymine, etc.) attached to a peptide backbone 
through a suitable linker. These ligands are linked to the 
polyamide backbone through aZa nitrogen atoms or through 
amido and/or ureido tethers. 
In certain preferred embodiments, the peptide nucleic 
acids of the invention have the general formula (I): 
Wherein: 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroxy, (C1—C4)alkanoyl, 
naturally occurring nucleobases, non-naturally occur 
ring nucleobases, aromatic moieties, DNA 
intercalators, nucleobase-binding groups, heterocyclic 
moieties, and reporter ligands, at least one of L1—L” 
being a naturally occurring nucleobase, a non-naturally 
occurring nucleobase, a DNA intercalator, or a 
nucleobase-binding group; 
each of C1—C” is (CR6R7)y Where R6 is hydrogen and R7 
is selected from the group consisting of the side chains 
of naturally occurring alpha amino acids, or R6 and R7 
are independently selected from the group consisting of 
hydrogen, (C2—C6)alkyl, aryl, aralkyl, heteroaryl, 
hydroxy, (C1—C6)alkoxy, (C1—C6)alkylthio, NR3R4 and 
SR5, Where R3 and R4 are as de?ned above, and R5 is 
hydrogen, (C1—C6)alkyl, hydroxy-, alkoxy-, or 
alkylthio-substituted (C1—C6)alkyl, or R6 and R7 taken 
together complete an alicyclic or heterocyclic system; 
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each of D1—D” is (CR6R7) Where R6 and R7 are as de?ned 
above; 
each of y and Z is Zero or an integer from 1 to 10, the sum 
y+Z being greater than 2 but not more than 10; 
Where R3 is as de?ned above; 
each pair of A1—A” and B1—B” are selected such that: 
(a) A is a group of formula (Ila), (IIb) or (IIc) and B is 
N or R3N+; or 
(b) A is a group of formula (IId) and B is CH; 
(Ila) 
(IIb) 
(IIc) 
(IId) 
4 
Where: 
X is O, S, Se, NR3, CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4; 
each of p and q is Zero or an integer from 1 to 5, the 
sum p+q being not more than 10; 
each of r and s is Zero or an integer from 1 to 5, the 
sum r+s being not more than 10; 
each R1 and R2 is independently selected from the 
group consisting of hydrogen, (C1—C4)alkyl Which 
may be hydroXy- or alkoXy- or alkylthio 
substituted, hydroXy, alkoXy, alkylthio, amino and 
halogen; 
15 each of G1—G"_1 is —NR3CO—, —NR3CS—, 
—NR3SO— or —NR3SO2—, in either orientation, 
Where R3 is as de?ned above; 
Q is —CO2H, —CONR‘R“, —SO3H or —SO2NR‘R“ 
or an activated derivative of —CO2H or —SO3H; 
and 
I is —NHR‘"R““ or —NR‘"C(O)R““, Where R‘, R“, R‘" 
and R““ are independently selected from the group 
consisting of hydrogen, alkyl, amino protecting 
25 groups, reporter ligands, intercalators, chelators, 
peptides, proteins, carbohydrates, lipids, steroids, 
nucleosides, nucleotides, nucleotide diphosphates, 
nucleotide triphosphates, oligonucleotides, oligo 
nucleosides and soluble and non-soluble polymers. 
30 . . . 
In certain embodiments, at least one A is a group of 
formula (IIc) and B is N or R3N+. In other embodiments, A 
is a group of formula (Ila) or (IIb), B is N or R3N+, and at 
least one of y or Z is not 1 or 2. 
35 Preferred peptide nucleic acids have general formula 
(IIIa)—(IIIc): 
(Illa) 
l l 
O (CH2)1 O (CH2)1 
Y O Y 
(91mm NV (CH2)1:n\ g (91mm NV (CH2)m\ NH_Ri 
0 R7’ p n R7’ p 
(IIIb) 
\ L\ (CH2)1 (CH2)1 
raw/k0 R3N o O 
(CH2)k 
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-continued 
L \ (CH2)1 
0 NR3 0 
O 
h 
R (cH?km NV (CH2)m\ g 
7, O R p 
n 
wherein: 
each L is independently selected from the group consist 
ing of hydrogen, phenyl, heterocyclic moieties, natu 
rally occurring nucleobases, and non-naturally occur 
ring nucleobases; 
each R7’ is independently selected from the group con 
sisting of hydrogen and the side chains of naturally 
occurring alpha amino acids; 
n is an integer from 1 to 60; 
each of k, l, and m is independently Zero or an integer 
from 1 to 5; 
p is Zero or 1; 
Rh is OH, NH2 or —NHLysNH2; and 
Ri is H or COCH3. 
Particularly preferred are compounds having formula (IIIa)— 
(IIIc) Wherein each L is independently selected from the 
group consisting of the nucleobases thymine (T), adenine 
(A), cytosine (C), guanine (G) and uracil (U), k and m are 
Zero or 1, and n is an integer from 1 to 30, in particular from 
4 to 20. 
The peptide nucleic acids of the invention are synthesiZed 
by adaptation of standard peptide synthesis procedures, 
either in solution or on a solid phase. The synthons used are 
monomer amino acids or their activated derivatives, pro 
tected by standard protecting groups. The PNAs also can be 
synthesiZed by using the corresponding diacids and 
diamines. 
Thus, the novel monomer synthons according to the 
invention are selected from the group consisting of amino 
acids, diacids and diamines having general formulae: 
(IV) 
OT 
(V) 
(VI) 
Wherein L, A, B, C and D are as de?ned above, eXcept that 
any amino groups therein may be protected by amino 
L 
(IIIc) 
15 
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protecting groups; E is COOH, CSOH, SOOH, SOZOH or an 
activated derivative thereof; and F is NHR3 or NPgR3, 
Where R3 is as de?ned above and Pg is an amino protecting 
group. 
Preferred monomer synthons according to the invention 
have formula (VIIIa)—(VIIIc): 
(VIIIa) 
L 
O (CH2)1 
HO (CH2)k N (CH2)m 
\H/ Y \/ \ NH2 
0 R7’ 
(VIIIb) 
L \ (CH2)1 
R3N 0 
HO (CH2)k (CH2)m\ \H/ NH2 
0 R7’ 
P 
(VIIIc) 
L \ ((IZH2)1 
0 NR3 
or amino-protected and/or acid terminal activated deriva 
tives thereof, Wherein L is selected from the group consisting 
of hydrogen, phenyl, heterocyclic moieties, naturally occur 
ring nucleobases, and non-naturally occurring nucleobases; 
and R7’ is selected from the group consisting of hydrogen 
and the side chains of naturally occurring alpha amino acids. 
These compounds are able to recogniZe one another to 
produce double helices. Such recognition can span 
sequences 5—60 base pairs long. Sequences betWeen 10 and 
20 bases are of interest since this is the range Within Which 
unique DNA sequences of prokaryotes and eukaryotes are 
found. Sequences betWeen 17—18 bases are of particular 
interest since this is the length of unique sequences in the 
human genome. 
Thus, in one aspect, the present invention provides meth 
ods for modulating the activity of a transcription factor in a 
cell, comprising the steps of forming a PNA-containing 
double strand that binds the transcription factor and intro 
ducing the double strand into the cell. 
Further, the invention provides methods for modulating 
the activity of a protein in a cell, comprising the steps of 
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forming a PNA-containing double strand that binds to or 
suppresses expression of the protein and introducing the 
double strand into the cell. 
The PNA duplex structures of the invention mimic 
dsDNA and can be used in diagnostics, therapeutics and as 
research reagents and kits. They can be used in pharmaceu 
tical compositions by including a suitable pharmaceutically 
acceptable diluent or carrier. 
BRIEF DESCRIPTION OF THE FIGURES 
The numerous objects and advantages of the present 
invention may be better understood by those skilled in the art 
by reference to the accompanying ?gures, in Which: 
FIG. 1 is a plot shoWing titration to saturation of a 10 mer 
PNA to a complementary 10 mer PNA. 
FIG. 2 is the development in time of the circular dichro 
ism signal of certain compounds of the invention. 
FIG. 3 is an Arrhenius plot of reaction rates at various 
temperatures during helical duplexation. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As Will be recogniZed, a variety of double-stranded (i.e., 
duplex) PNA-containing structures can be prepared accord 
ing to the present invention. Representative duplexes can be 
formed Within a single homopolymeric PNA strand or a 
single heteropolymeric strand (e.g., a chimera PNA-DNA or 
PNA-RNA strand), or betWeen tWo homopolymeric PNA 
strands, tWo heteropolymeric PNA strands, or a homopoly 
meric PNA strand and a heteropolymeric PNA strand. 
Each PNA strand or PNA portion of a chimera strand 
preferably comprises a plurality of ligands, L, linked to a 
backbone via attachment at the position found in nature, i.e., 
position 9 for adenine or guanine, and position 1 for thymine 
or cytosine. Alternatively, L can be a non-naturally occurring 
nucleobase (nucleobase analog), another base-binding 
moiety, an aromatic moiety, (C1—C4)alkanoyl, hydroxy or 
even hydrogen. It Will be understood that the term nucleo 
base includes nucleobases bearing removable protecting 
groups. Some typical nucleobase ligands and illustrative 
synthetic ligands are shoWn in FIG. 2 of WO 92/20702. 
Furthermore, L can be a DNA intercalator, a reporter ligand 
such as, for example, a ?uorophor, radio label, spin label, 
hapten, or a protein-recogniZing ligand such as biotin. In 
monomer synthons, L can be blocked With protecting 
groups, as illustrated in FIG. 4 of WO 92/20702. 
Linker A can be a Wide variety of groups such as 
—CR1R2CO—, —CR1R2CS—, —CR1R2CSe—, 
—CR1R2CNHR3—, —CR1R2C=CH2— and 
—CR1R2C=C(CH3)2—, Where R1, R2 and R3 are as 
de?ned above. Preferably, A is methylenecarbonyl 
(—CH2CO—), amido (—CONR3—), or ureido 
(—NR3CONR3—). Also, A can be a longer chain moiety 
such as propanoyl, butanoyl or pentanoyl, or corresponding 
derivative, Wherein O is, replaced by another value of X or 
the chain is substituted With RlR2 or is heterogenous, 
containing Y. Further, A can be a (C2—C6)alkylene chain, a 
(C2—C6)alkylene chain substituted With RlR2 or can be 
heterogenous, containing Y. In certain cases, A can just be a 
single bond. 
In one preferred form of the invention, B is a nitrogen 
atom, thereby presenting the possibility of an achiral back 
bone. B can also be R3N+, Where R3 is as de?ned above, or 
CH. 
In the preferred form of the invention, C is —CR6R7—, 
but can also be a tWo carbon unit, i.e. —CHR6CHR7— or 
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8 
—CR6R7CH2—, Where R6 and R7 are as de?ned above. R6 
and R7 also can be a heteroaryl group such as, for example, 
pyrrolyl, furyl, thienyl, imidaZolyl, pyridyl, pyrimidinyl, 
indolyl, or can be taken together to complete an alicyclic 
system such as, for example, 1,2-cyclobutanediyl, 1,2 
cyclopentanediyl or 1,2-cyclohexanediyl. 
In a preferred form of the invention, E in the monomer 
synthon is COOH or an activated derivative thereof, and G 
in the oligomer is —CONR3—. As de?ned above, E also can 
be CSOH, SOOH, SO2OH or an activated derivative 
thereof, Whereby G in the oligomer becomes —CSNR3—, 
—SONR3— and —SO2NR3—, respectively. The activation 
can, for example, be achieved using an acid anhydride or an 
active ester derivative, Wherein hydrogen in the groups 
represented by E is replaced by a leaving group suited for 
generating the groWing backbone. 
The amino acids Which form the backbone can be iden 
tical or different. We have found that those based on 
2-aminoethyl-glycine are especially Well suited to the pur 
pose of the invention. 
In some cases it may be of interest to attach ligands at 
either terminus (Q, I) to modulate other properties of the 
PNAs. Representative ligands include DNA intercalators or 
basic groups, such as lysine or polylysine. Further groups 
such as carboxy and sulfo groups could also be used. The 
design of the synthons further alloWs such other moieties to 
be located on non-terminal positions. 
Duplexes according to the present invention can be 
assayed for their speci?c binding activity to a transcription 
factor. As used herein, the term “binding af?nity” refers to 
the ability of a duplex to bind to a transcription factor via 
hydrogen bonds, van der Waals interactions, hydrophobic 
interactions, or otherWise. For example a duplex can bind to 
a “leucine Zipper” transcription factor or a helix-loop-helix 
transcription factor via positively charged amino acids in 
one region of the transcription factor. 
Transcription factors, as the term is used herein, are DNA 
or RNA-binding proteins that regulate the expression of 
genes. HIV tat and c-rel are examples of transcription factors 
Which regulate the expression of genes. Also encompassed 
by the term are DNA and RNA binding proteins Which are 
not strictly considered transcription factors, but Which are 
knoWn to be involved in cell proliferation. These transcrip 
tion factors include c-myc, fos, and jun. Methods of the 
present invention are particularly suitable for use With 
transcription factor as target molecules since transcription 
factors generally occur in very small cellular quantities. 
The compounds of the present invention also may be 
useful to bind to other target molecules. Target molecules of 
the present invention can include any of a variety of bio 
logically signi?cant molecules. Such other target molecules 
can be nucleic acid strands such as signi?cant regions of 
DNA or RNA. Target molecules also can be carbohydrates, 
glycoproteins or other proteins. In some preferred embodi 
ments of the present invention, the target molecule is a 
protein such as an immunoglobulin, receptor, receptor bind 
ing ligand, antigen or enZyme and more speci?cally can be 
a phospholipase, tumor necrosis factor, endotoxin, 
interleukin, plasminogen activator, protein kinase, cell adhe 
sion molecule, lipoxygenase, hydrolase or transacylase. In 
other embodiments of the invention the target molecules can 
be important regions of the human immunode?ciency virus, 
Candida, herpes viruses, papillomaviruses, 
cytomegalovirus, rhinoviruses, hepatitises, or in?uenZa 
viruses. In yet other embodiments of the present invention 
the target molecules can be regions of an oncogene. In still 
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further embodiments, the target molecule is ras 47-mer stem 
loop RNA, the TAR element of human immunode?ciency 
virus or the gag-pol stem loop of human immunode?ciency 
virus (HIV). Still other targets can induce cellular activity. 
For example, a target can induce interferon. 
In binding to transcription factors or other target 
molecules, the transcription factor or other target molecule 
need not be puri?ed. It can be present, for example, in a 
Whole cell, in a humoral ?uid, in a crude cell lysate, in serum 
or in other humoral or cellular extract. Of course, puri?ed 
transcription factor or a puri?ed form of an other target 
moleucle is also useful in some aspects of the invention. 
In still other embodiments of the present invention, syn 
thetically prepared transcription factor or other target 
moleucle can be useful. A transcription factor or other target 
moleucle also can be modi?ed, such as by biotinylation or 
radiolabeling. For example, synthetically prepared transcrip 
tion factor can incorporate one or more biotin molecules 
during synthesis or can be modi?ed post-synthesis. 
An illustrative series of PNA oligomers according to the 
invention can be prepared as described in Example 1 beloW 
and have been designed as folloWs: 
(1) Formulas 1 (SEQ ID NO:1) and 2 (SEQ ID NO:2), tWo 
complementary antiparallel PNA decamers that are not 
self-complementary: 
(aminoterminal) H-Gly-GTAGATCACT-LysNH2 1 
LysNH2—CATCTAGTGA—GlyH (aminoterminal) 2 
(2) Formula 3 (SEQ ID NO:3), a single PNA oligomer 
possessing a self-complementary motif ten base pairs long 
With an intervening loop region containing ?ve base units: 
3 
H- Gly-GTAGATCACT-TT 
T 
LysNHT CATCTAGTGA-TT 
(3) Formula 4 (SEQ ID NO:4), a single PNA oligomer 
possessing a self complementary motif of ten base pairs long 
linked by an oligomethylene (n=1—10) spacer: 
H-GlyGTAGATCACT-(CHQH 
LySNHZ-CATCTAGTGA-CHZ 
(4) Formula 5 (SEQ ID NO:5), a single PNA oligomer 
possessing a self-complementary motif ten base pairs long 
on one side interrupted by a three base bulge and an 
intervening loop region containing ?ve base units: 
TAT 
H-GlyGTAGAT CACT-TT 
T 
LysNH2—CATCTA GTGA-TT 
In each of the foregoing, LysNH2 is intended to indicate that 
a lysine-amide is attached to the carboxyl end of the PNA. 
Use of such lysine-amide is not necessary; hoWever, its use 
is preferred since it is believed to suppress aggregation of the 
oligomers. The aminoterminal end of the PNA is substituted 
With a glycine residue to avoid migration of the N-terminal 
nucleobase. The PNA amino-terminal and carboxy-terminal 
ends are intended to correspond, respectively, to the 5‘-ends 
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10 
and 3‘-ends of DNA. As a consequence of the designed 
sequences, these PNAs form duplexes having DNA-like 
antiparallel orientations. These PNAs additionally are 
capable of adopting a tertiary structure. 
As can be seen in FIG. 1, the circular dichroism (CD) of 
PNA 10-mers of Example 1 are almost vanishingly small, 
indicating that there is no preferred helical stacking of bases. 
HoWever, a strong CD spectrum arises upon titration of one 
10-mer With the complementary 10-mer, a saturation 
obtained at about 1:1 stoichiometry, as shoWn in FIG. 2. The 
CD spectrum resembles that of B-DNA, indicating a right 
handed helix. It is believed that a PNA-PNA complex having 
no preferred helicity initially is formed. The kinetics by 
Which this double-stranded structure reorganiZes into a 
uniform, right-handed double helix has been monitored and 
the activation parameters for the process determined. 
For DNA, circular dichroism in the nucleobase absorption 
region arises both from helical stacking of the bases, by 
excitation interactions betWeen the neighboring bases, and 
from interactions With transitions of the chiral riboses moi 
eties. In contrast, in PNA the electronic interaction betWeen 
most of the bases and the chiral terminal lysine is negligible 
and the main source of circular dichroism is attributable 
almost solely to the chiral orientation of the base-pairs 
relative to each other. The right-handed helicity observed for 
PNA is determined by the chiral bias of a terminal lysine 
residue. The formation of a helical duplex betWeen the tWo 
complementary PNA oligomers Was sloW enough to be 
folloWed by the increase in circular dichroism With time. 
This is in contrast With DNA-DNA duplex formation, Which 
occurs Within seconds. The development of circular dichro 
ism folloWs ?rst order reaction kinetics. Activation param 
eters have been determined by folloWing the association at 
various temperatures, as shoWn in FIG. 3. Control experi 
ments With different PNA concentrations gave identical 
results, con?rming that the PNA-PNA association is fast and 
includes a reorganiZation process in an already base-paired 
complex. This observation is further supported by the 
absence of time dependent hypochromicity in normal 
absorption spectra. Such a reorganiZation in the correspond 
ing cases of DNA-DNA and DNA-PNA decamers duplexes 
is too fast to be observed, indicating that the local chirality 
of the ribose in those cases immediately determines the 
handedness of base stacking. The conclusion is that the 
association of the tWo PNA-oligomers is fast in the base 
pairing ?rst step, but is folloWed by a sloW seeding of the 
duplex chirality, from the terminal lysine residue, toWards its 
right-handed helical structure. The activation energy 
obtained is 33.9 kJ/mole, Which is loW because the transition 
state is associated With a large negative entropy change 
(AS=—173 kJ/mole; see, e.g., FIG. 3), implying a highly 
ordered transition state. This is a strong indication that the 
rate-limiting inversion step is a cooperative seeding of 
chirality from the terminal base-pairs involving the entire 
stack of bases. 
We believe this is the ?rst time a pure cooperative 
inversion transition in a nucleic acid-like structure has been 
isolated. Also, in contrast to DNA Wherein ribose residues 
act as local chiral centers, optical activity of PNA-PNA 
duplexes is entirely a result of the helical arrangement of the 
nucleo-bases relative to each other. The CD spectrum can be 
compared With the theoretical and experimental spectra that 
have been generated for helix stacks of DNA bases to 
demonstrate the mimicry of DNA duplex structure. These 
PNA-PNA duplexes therefore are useful mimics of DNA for 
the purpose of modulating the expression or transcription of 
DNA and thus modulating a disease state to the bene?t of a 
living organism. 
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The utility of these PNA-containing duplex structures can 
be illustrated by constructing PNA sequences Which corre 
spond to various sequences of the HIV TAR element that 
have the potential to form duplex structures either as stem 
loop structures or tWo PNAs forming a duplex structure. In 
a competition assay, PNA structures that bind the tat tran 
scription factor prevent binding of the competitor TAR 
sequence present in the incubation mixture. As the TAR 
RNA sequence is biotinylated only tat proteins available to 
bind to TAR Will remain on the microtiter plate after 
Washing aWay unbound molecules and tat protein com 
plexed to a PNA sequence. The concentration dependence of 
the competition betWeen the TAR PNA structures and bioti 
nylated TAR structure Will serve to de?ne those sequences 
capable of effectively competing for tat and thus useful as 
HIV modulatory agents. 
Additional objects, advantages, and novel features of this 
invention Will become apparent to those skilled in the art 
upon examination of the folloWing examples thereof, Which 
are not intended to be limiting. 
EXAMPLE 1 
Synthesis of PNA Structures 
PNA having formulas 1 through 5 above are prepared 
generally according to the synthetic protocols of our prior 
patent application WO 92/20702. Migration of the last 
nucleobase methylcarbonyl moiety to the terminal nitrogen 
is prevented by capping the N-terminus of the PNA chain 
With a glycine residue. The compounds are puri?ed by 
HPLC (reverse phase, 0.1% tri?uoroacetic acid in 
acetonitrile/Water) and the composition veri?ed by mass 
spectrometry. 
EXAMPLE 2 
Binding and Helix Formation of Complementary 
Antiparallel PNA Strands (FIG. 1) 
The circular dichroism spectra of PNA-PNA mixtures 
Were obtained by titrating PNA having sequence 
H-GTAGATCACT-LysNH2 (PNA formula 1) With PNA 
having sequence H-AGTGATCTAC-LysNH2 (PNA formula 
2). The concentration of PNA formula 1 Was held constant 
(50 pmole/L) and the concentration of PNA formula 2 Was 
increased to provide the folloWing formula 2:formula 1 
stoichiometries: 0.25 (Curve C), 0.50 (Curve D), 0.75 
(Curve E), 1.00 (Curve F), and 1.25 (Curve G). The hybrid 
iZations Were performed in a 5 mmol/L sodium phosphate 
buffer, pH 7.0, at 20° C., after 20 minutes of incubation. The 
path length Was 1 cm. Saturation Was obtained at equimolar 
amounts of the tWo decamers. 
FIG. 2 shoWs development of negative circular dichroism 
(at 220 nm) as a function of time after mixing equimolar 
amounts of PNA formula 1 With PNA formula 2. From top 
to bottom, the curves correspond to the folloWing tempera 
tures: 5° C., 15° C., 23° C., 32° C., 41° C., and 47° C. 
FIG. 3 shoWs an Arrhenius plot of rates from the CD 
kinetics. The plot provides the activation energy as AH=33.9 
kJ/mole (With the approximation that (k5T/h)exp(ASi/R) is 
constant). The full rate equation is k=(k3T/h)exp(—AH*)exp 
(ASi/R) then gives AS:l:=-173 J/mole. 
EXAMPLE 3 
PNA Having Binding Af?nity for The HIV-tat 
Protein as Measured in a Competitive Inhibition 
Assay 
Samples of PNAs corresponding to various TAR 
sequences prepared by the method of Example 1 are incu 
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bated With recombinant tat transcription factor (100 pM) for 
15 minutes at room temperature at 1, 3, 10 ,30, and 100 pM 
(see, e.g., Cullen, et al., Cell 1990, 63, 655.). Acompetitor, 
a truncated version of the TAR sequence corresponding to 
residues 16—45 as a 2‘-O-methyl oligonucleotide, is 
employed as a TAR sequence and is biotinylated at the 3‘-O 
end by procedures generally in accordance With the proto 
cols of application Ser. No. 08/032,852, Combinatorial 
Oligomer Immunoabsorbant Screening Assay For Transcrip 
tion Factors And Other Biomolecule Binding, ?led Mar. 16, 
1993, the entire contents of Which are incorporated herein by 
reference. This TAR sequence is added at 100 nM concen 
tration. The reaction is incubated for 20 minutes and then 
added to streptavidin-coated microtiter plate Wells. After 
unbound molecules are Washed aWay With phosphate 
buffered saline (PBS), 100 pL of 1:500 tat antisera is added 
to each Well and incubated for 2 hours. Protein A/G antisera 
phosphatase is bound to the tat antibodies and PNPP 
(p-nitrophenylphosphate) substrate (200 pl) then is added. 
Color development is measured 2 hours later by reading 
absorbance at 405 nM on a Titertek Multiscan ELISA plate 
reader. 
EXAMPLE 4 
PNA Having Binding Af?nity for the C-myc 
Protein 
Myc-c is a nuclear protein involved in cell proliferation, 
differentiation, and neoplastic disease and binds DNA in a 
sequence speci?c manner. See, e.g., Nissen, Cancer 
Research 1986, 46, 6217 and Blackwell, Science 1990, 250, 
1149. Crude nuclear extracts of myc-c are prepared gener 
ally in accordance With FranZa, et al., Nature 1987, 330, 391, 
from HL 60 cells stimulated to induce the expression of 
myc-c. 
Phosphorothioate oligonucleotides having the sequences 
GAT CCC CCC ACC ACG TGG TGC CTG A-B (SEQ ID 
N016) and GAT CTC AGG CAC CAC GTG GTG GGG 
G-B (SEQ ID NO:7), Where B=biotin, are synthesiZed on an 
automated DNA synthesiZer (Applied Biosystems model 
380B) using modi?ed standard phosphoramidite chemistry 
With oxidation by a 0.2M solution of 3H-1,2-benZodithiole 
3-one 1,1-dioxide in acetonitrile for stepWise thiation of 
phosphite linkages. The thiation cycle Wait step is 68 sec 
onds and is folloWed by the capping step. 
[3-Cyanoethyldiisopropyl phosphoramidites can be pur 
chased from Applied Biosystems (Foster City, Calif.). Bases 
are deprotected by incubation in methanolic ammonia over 
night. FolloWing base deprotection, the oligonucleotides are 
dried in vacuo. Removal of 2‘-hydroxyl t-butyldimethylsilyl 
protecting groups is effected by incubating the oligonucle 
otide in 1M tetrabutylammonium ?uoride in tetrahydrofuran 
overnight. The RNA oligonucleotides are further puri?ed on 
C18 Sep-Pak cartridges (Waters, Division of Millipore 
Corp., Milford, Mass.) and ethanol precipitated. The phos 
phorothioate oligonucleotides are hybridiZed to create the 
double stranded NF-kB binding site. 
Aseries of PNA-PNA duplexes is synthesiZed and hybrid 
iZed to give a neW series of PNA duplexes corresponding to 
different length portions of the myc-c binding sequence. 
Each duplex is incubated in triplicate at concentrations of 1, 
3, 10, 30, and 100 pM With the HL-60 extract described 
above. The myc P=S binding site then is added and the 
mixtures are incubated and Washed With PBS. An antibody 
directed to the leucine Zipper region of the myc protein 
(Santa CruZ Biotechnology) is added at a 1:1000 dilution. 
Non-bound molecules are Washed aWay With PBS. Binding 
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of myc to biotinylated c-myc transcription factor is quanti 
tated by adding 100 pl of 1:500 tat antisera to each Well for 
2 hours. Protein A/G-alkaline phosphatase (Pierce; 15000; 
100 pl) then is added and any excess is removed by Washing 
With PBS. PNPP substrate (200 pl) then is added. Color 
development is measured 2 hours later by reading absor 
bance at 405 nM on a Titertek Multiscan ELISAplate reader. 
EXAMPLE 5 
PNA Having Binding Af?nity for the C-rel 
Transcription Factor 
C-rel has been shoWn to represent a constituent of the 
NF-kB site binding transcription factor, Which plays a 
crucial role in the expression of a number of genes including 
the immunoglobulin k light chain gene, IL-2ra, and MHC. 
(see, e.g., Gilmore, et al., Cell 1986, 62, 791.) 
Crude nuclear extracts are prepared as detailed by Emma, 
et al., Nature 1987, 330, 391, from Jurkat cells stimulated 4 
hours With 1 pM PHA and 100 nM PMA to induce the 
expression of rel. The extract is then preabsorbed With 100 
pl streptavidin agarose per ml for 10 minutes. This is 
folloWed With the addition of poly dI.dC as a nonspeci?c 
competitor at a concentration of 100 pig/ml of extract. 
Nuclear extracts containing the biotinylated NF-kB binding 
site competitor are prepared as in Example 4, above. 
Aseries of PNA duplexes is synthesiZed to correspond to 
various length fragments of the consensus binding sequence 
of c-rel. NF-kB binding site competitor is added to each 
duplex and the resulting samples are Washed. Antibody 
directed to rel is added. The amount of rel bound is quan 
titated by adding 100 pl of 1:500 rel antisera to each Well for 
2 hours. Protein A/G-alkaline phosphatase (Pierce; 15000; 
100 pl) the is added and any excess is removed by Washing 
With PBS. PNPP substrate (200 pl) then is added. Color 
development is measured 2 hours later by reading absor 
bance at 405 nM on a Titertek Multiscan ELISAplate reader. 
EXAMPLE 6 
PNA Having Binding Af?nity for the AP-1 
Transcription Factor 
Genes belonging to the fos and jun oncogene families 
encode nuclear proteins associated With a number of tran 
scriptional complexes, see, eg , Konig, et al. , EMBO 
Journal 1989, 8, 2559. C-jun is a major component of the 
AP-1 binding site, Which Was originally shoWn to regulate 
tissue plasminogen activator (TPA) induced expression of 
responsive genes through the TPA response element (TRE). 
The jun protein forms homo- or heterodimers Which bind the 
TRE. The fos protein is only active as a heterodimer With 
any of the jun family of proteins. Fos/jun heterodimers have 
a much higher affinity for the TRE than jun homodimers. 
Both the fos and the jun cDNA have been cloned doWn 
stream of the Sp6 promoter. RNA is produced from each 
plasmid in vitro, then used to produce functional jun and fos 
proteins in rabbit reticulocyte lystates. The fos and jun 
proteins are then alloWed to bind to the biotinylated AP-1 
binding site in competition With PNA duplex sequences 
constructed as mimics of the proper consensus sequence for 
binding fos and jun, CGC TTG GTG ACT CAG CCG GAA. 
Binding is quantitated With an antibody directed to fos or 
jun. When the fos alone is incubated With the AP-1 site there 
Will be no detectable binding With either antibody. When the 
jun alone is incubated With the binding site, a signal Will be 
detected With only the jun antibody. This is consistent With 
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the formation of a jun homodimer, Which has previously 
been demonstrated to bind AP-1. When the fos and jun 
proteins are mixed a signal Will be detected With both fos 
and jun antibodies. This is consistent With the formation of 
a fos/jun homodimer Which is knoWn to bind the AP-1 site 
and should be detectable With either antibody. 
PNA sequences of the present invention can be tested for 
the ability to block the formation of the fos/jun heterodimer. 
Molecules Which block formation Will decrease the signal 
detected With the fos antibody, but not the jun antibody. 
EXAMPLE 7 
Chimera Macromolecule Having Peptide Nucleic 
Acids Section Attaching to 3‘ Terminus of a 2‘ 
Deoxy Phosphorothioate Oligonucleotide Section 
A ?rst section of peptide nucleic acids is prepared as per 
PCT patent application WO 92/20702. The peptide nucleic 
acids are prepared from the C terminus toWards the N 
terminus using monomers having protected amino groups. 
FolloWing completion of the peptide region, the terminal 
amine blocking group is removed and the resulting amine 
reacted With a 3‘-C-(formyl)-2‘,3‘-dideoxy-5‘-trityl nucle 
otide as prepared per the procedure of Vasseur, et. al., J. Am. 
Chem. Soc. 1992, 114, 4006. The condensation of the amine 
With the aldehyde moiety of the C-formyl nucleoside is 
effected as per the conditions of the Vasseur, ibid., to yield 
an intermediate imine linkage. The imine linkage is reduced 
under reductive the alkylation conditions of Vasseur, ibid., 
With HCHO/NaBH3CN/AcOH to yield the nucleoside con 
nected to the peptide nucleic acid via an methyl alkylated 
amine linkage. An internal 2‘-deoxy phosphorothioate nucle 
otide region is then continued from this nucleoside as per 
standard automatated DNA synthetic protocols (see Oligo 
nucleotide synthesis, a practic approach, M. J. Gait ed, IRL 
Press, 1984). 
EXAMPLE 8 
Chimera Macromolecule Having Peptide Nucleic 
Acids Section Attaching to 5‘ Terminus of a 
Phosphorothioate Oligonucleotide Section 
A phosphorothioate oligonucleotide is prepared in the 
standard manner on a solid support as per standard protocols 
(see Oligonucleotides and Analogues, A Practical Approach, 
F. Eckstein Ed., IRL Press, 1991. The dimethoxytrityl block 
ing group on that nucleotide is removed in the standard 
manner. Peptide synthesis for the peptide region is com 
menced by reaction of the carboxyl end of the ?rst peptide 
nucleic acid of this region With the 5‘ hydroxy of the last 
nucleotide of the DNA region. Coupling is effected via EDC 
(Pierce) in pyridine to form an ester linkage betWeen the 
peptide and the nucleoside. Peptide synthesis is then con 
tinued in the manner of patent application WO 92/20702 to 
complete the peptide nucleic acid region. 
EXAMPLE 9 
Double Stranded Structures that Include Chimera 
Strand 
Duplex structures Will be formed With the chimera strands 
of Examples 7 and 8. Duplex structures can include duplexes 
betWeen a PNA-RNA or PNA-DNA strand and a RNA 
strand, a PNA-RNA or PNA-DNA strand and a DNA strand, 
a PNA-RNA or PNA-DNA strand and a PNA strand or a 
PNA-RNA or PNA-DNA strand and a further chimeric 
PNA-DNA or PNA-RNA strand. 
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EXAMPLE 10 
Binding Between PNA Containing Double Stranded 
Structure and Transcription Factor or Other Protein 
A double stranded PNA structure, a structure containing 
PNA chimeric strand and a nucleic acid strand or tWo PNA 
chimera strands Will be used to bind to or otherWise modu 
late single stranded DNA, double stranded DNA, RNA, a 
transcription factor or other protein. In the use of a PNA 
containing chimera, part of the binding betWeen the chimera 
and the transcription factor or other protein can include 
binding betWeen the sugar-phosphate backbone of the DNA 
or RNA portion of the chimera and hydrogen bonding 
betWeen the ligands, e.g. nucleobases, of the PNAportion of 
the chimera. Binding to the sugar-phosphate backbone 
includes binding to phosphodiester linkages, phosphorothio 
15 
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ate linkages or other linkgages that may be used as the 
bacbone of the DNA or RNA. In other instances, bonding 
can include hydrophobic contacts betWeen hydrophobic 
groups on the ligands, including nucleobases, of the PNA or 
the nucleobases of the nucleic acid portion of the chimera 
With like hydrophobic groups on proteins that are being 
bound. Such hydrophobic groups on the chimeric strand 
include the methyl groups on thymine nucleobases. 
Those skilled in the art Will appreciate that numerous 
changes and modi?cations can be made to the preferred 
embodiments of the invention and that such changes and 
modi?cations can be made Without departing from the spirit 
of the invention. It is therefore intended that the appended 
claims cover all such equivalent variations as fall Within the 
true spirit and scope of the invention. 
SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 12 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic construct 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (2)..(2) 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (3)..(4) 
<220> 
<22l> 
<222> 
<223> 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (5)..(5) 
<220> 
<22l> 
<222> 
<223> 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (6)..(7) 
<220> 
<22l> 
<222> 
<223> 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (8)..(8) 
<220> 
<22l> 
<222> 
<223> 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (9)..(9) 
<220> 
<22l> 
<222> 
<223> 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (10) .. (10) 
<220> 
<22l> 
<222> 
<223> 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (11)..(11) 
OTHER INFORMATION: Heterocyclic base 
OTHER INFORMATION: Heterocyclic base is attached 
OTHER INFORMATION: Heterocyclic base is attached 
OTHER INFORMATION: Heterocyclic base is attached 
OTHER INFORMATION: Heterocyclic base is attached 
OTHER INFORMATION: Heterocyclic base is attached 
OTHER INFORMATION: Heterocyclic base is attached 
OTHER INFORMATION: Heterocyclic base is attached 
is attached 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
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-continued 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<400> SEQUENCE: 1 
Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys 
1 5 l0 
<2 10> SEQ ID NO 2 
<2ll> LENGTH: 12 
<2 12> TYPE: PRT 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic construct 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (2) . . (2 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (3) . . (4 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (5) . . (5 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (6) . . (7 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (8) . . (8 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (9) . . (9 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( 10 ) . . ( 10 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( 11 ) . . ( 11 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<400> SEQUENCE: 2 
Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly 
l 5 l0 
<2 10> SEQ ID NO 3 
<2ll> LENGTH: 27 
<2 12> TYPE: PRT 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic construct 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (2) . . (2 ) 
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OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (3) . . (4) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (5) . . (5) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (6) . . (7) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (8) . . (8) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (9) . . (9) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (10 ) . . ( 10) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (11) . . ( 17) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (18 ) . . ( 18) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (19 ) . . ( 19) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (20 ) . . (20) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (21 ) . . (22) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (23) . . (23) 
to 
to 
to 
to 
to 
to 
to 
to 
to 
to 
to 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl group at position 9 of 
the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (24 ) . . (25) 
OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
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(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (26 ) . . (26 ) 
OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
SEQUENCE: 3 
Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
l 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
5 l0 l5 
Lys 
20 25 
SEQ ID NO 4 
LENGTH: 22 
TYPE: PRT 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic construct 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (2) . . (2 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (3) . . (4 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (5) . . (5 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (6) . . (7 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (8) . . (8 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (9) . . (9 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: ( 10 ) . . ( 10 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: ( 11 ) . . ( 12 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: ( 13 ) . . ( 13 ) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
to N-acetyl 
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-continued 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( 14 ) . . ( 14 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( 15 ) . . ( 15 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( l6 ) . . ( 17 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( l8 ) . . ( l8 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( 19 ) . . (20 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (21 ) . . (21 ) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE: 4 
Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
l 5 l0 l5 
Xaa Xaa Xaa Xaa Xaa Lys 
20 
<2 10> SEQ ID NO 5 
<2ll> LENGTH: 30 
<2 12> TYPE: PRT 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic construct 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (2) . . (2 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (3) . . (4 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (5) . . (5 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (6) . . (10) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: ( 11 ) . . ( 11 ) 
<223> OTHER INFORMATION: Heterocyclic base is attached to N-acetyl 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
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-continued 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (12) . . (12) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (13) . . (13) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (14 ) . . (20) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (21 ) . . (21) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (22 ) . . (22) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (23) . . (23) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (24 ) . . (25) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (26) . . (26) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (27 ) . . (28) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 1 of the base 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (29) . . (29) 
OTHER INFORMATION: Heterocyclic base is attached 
(2-aminoethyl) glycine through the N-acetyl 
group at position 9 of the base 
SEQUENCE: 5 
to 
to 
to 
to 
to 
to 
to 
to 
to 
to 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
N-acetyl 
Gly Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
15 l 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys 
2O 25 3O 
SEQ ID NO 6 
LENGTH: 25 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Synthetic construct 
FEATURE: 
NAME/KEY: miscifeature 
LOCATION: (25) . . (25) 
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-continued 
<223> OTHER INFORMATION: /note= "biotin labeled" 
<400> SEQUENCE: 6 
gatcccccca ccacgtggtg cctga 
<2 10> SEQ ID NO 7 
<2ll> LENGTH: 25 
<2 12> TYPE: DNA 
<2 13> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Synthetic construct 
<220> FEATURE: 
<22l> NAME/KEY: miscifeature 
<222> LOCATION: (25)..(25) 
<223> OTHER INFORMATION: /note= "biotin labeled" 
<400> SEQUENCE: 7 
gatctcaggc accacgtggt ggggg 
25 
25 
What is claimed is: 
1. A process comprising the steps of: 
providing a cell comprising a transcription factor; 
forming a double-stranded structure by: 
providing a ?rst strand and a second strand, each strand 
comprising a peptide nucleic acid moiety that 
includes a sequence of ligands covalently bound by 
linking moieties, Wherein at least a portion of said 
ligands bind said transcription factor; and 
disposing said strands relative to one another to form 
hydrogen bonds therebetWeen and thereby form a 
double strand; and 
introducing said double-stranded structure into said cell. 
2. The process of claim 1 Wherein at least tWo of said 
linking moieties in a strand have both amino ends and 
carboXyl ends and said linking moieties are covalently 
bound via amide linkages. 
3. The process of claim 2 Wherein each of said linking 
moieties includes a nitrogen atom betWeen said amino end 
and said carboXyl end. 
4. The process of claim 3 Wherein each of said ligands is 
connected to said linking moieties via said nitrogen atoms. 
5. The process of claim 1 Wherein at least one of said 
strands has the formula: 
Wherein: 
n is at least 2, 
each of L1—L” is independently selected from the group 
consisting of hydrogen, hydroXy, (C1—C4)alkanoyl, 
naturally occurring nucleobases, non-naturally occur 
ring nucleobases, aromatic moieties, DNA 
intercalators, nucleobase-binding groups, heterocyclic 
moieties, and reporter ligands; 
each of C1—C” is (CR6R7)y Where R6 is hydrogen and R7 
is selected from the group consisting of the side chains 
of naturally occurring alpha amino acids, or R6 and R7 
are independently selected from the group consisting of 
hydrogen, (C2—C6)alkyl, aryl, aralkyl, heteroaryl, 
hydroXy, (C1—C6)alkoXy, (C1—C6)alkylthio, NR3R4 and 
SR5, Where R3 and R4 are as de?ned above, and R5 is 
hydrogen, (C1—C6)alkyl, hydroXy-, alkoXy-, or 
alkylthio-substituted (C1—C6)alkyl, or R6 and R7 taken 
together complete an alicyclic or heterocyclic system; 
25 
35 
45 
65 
each of D1—D” is (CR6R7)Z Where R6 and R7 are as de?ned 
above; 
each of y and Z is Zero or an integer from 1 to 10, the sum 
y+Z being greater than 2 but not more than 10; 
each of G1—G”_1 is —NR3CO—, —NR3CS—, 
—NR3SO— or —NR3SO2—, in either orientation, 
Where R3 is as de?ned above; 
each of A1—A” and B1—B” are selected such that: 
(a) Ais a roup of formula (Ila), (IIb) or (IIc), and B is 
N or R +; or 
(b) A is a group of formula (IId) and B is CH; 
X is O, S, Se, NR3, CH2 or C(CH3)2; 
Y is a single bond, O, S or NR4; 
each of p and q is Zero or an integer from 1 to 5, 
the sum p+q being not more than 10; 
each of r and s is Zero or an integer from 1 to 5, 
the sum r+s being not more than 10; 
each R1 and R2 is independently selected from 
the group consisting of hydrogen, (C1—C4) 
alkyl Which may be hydroXy- or alkoXy- or 
alkylthio-substituted, hydroXy, alkoXy, 
alkylthio, amino and halogen; and 
each R3 and R4 is independently selected from 
the group consisting of hydrogen, (C1—C4) 
alkyl, hydroXy- or alkoXy- or alkylthio 
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Substituted (C1—C4)a1kY1> hydroxy, a1kOXy> alkylthio and amino; proteins, carbohydrates, lipids, steroids, nucleosides, 
Q is —CO2H, CONR‘R“, —SO3H or —SO2NR'R" or nucleotides, nucleotide diphosphates, nucleotide 
an activated derivative of —CO2H 0r —SO3H; and triphosphates, oligonucleotides, oligonucleosides and 
I is —NHR‘"R““ or —NR‘"C(O)R““, Where R‘, R“, R‘" soluble and non-soluble polymers. 
and R““ are independently selected from the group 5 6. The process of claim 5 Wherein each of said ?rst and 
consisting of hydrogen, alkyl, amino protecting groups, second polymeric strands comprises a moiety of the for 
reporter ligands, intercalators, chelators, peptides, mula: 
L l 
O (CH2)1 O (CH2)1 
O Y 
Rh (CH2)k NV (CH2)1:n\ (CH2)k NV (CH2)m\ i 
N NH—R 
H 
7' 7' O R p R p 
H 
or the formula 
L L \ \ 
(CH2)1 ?r 
R3N o o R3N o 
Rh (CH2)k (CH2)1:n\ (CH2)k (CH2)m\ _ 
N NH—Rl 
H 
7' 7 O R p R p 
H 
or the formula 
L L \ \ (CH2)1 (CH2)1 
0 NR3 0 NR3 
0 Y 
Rh (CH2)k N (CH2)m (CH2)k N (CH2)m _ \/ \N \/ \NH_R1 
H 
7' 7' 
O R p n R p 
Wherein: 
each L is independently selected from the group consist 
ing of hydrogen, phenyl, heterocyclic moieties, natu 
rally occurring nucleobases, and non-naturally occur 
ring nucleobases; 
50 
each R7’ is independently selected from the group con 
55 sisting of hydrogen and the side chains of naturally 
occurring alpha amino acids; 
n is an integer greater than 1, 
each k, l, and m is, independently, Zero or an integer from 
1 to 5; 
each p is Zero or 1; 
Rh is OH, NH2 or —NHLysNH2; and 
R' is H or COCH3. 
* * * * * 
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